EG 427

Paris, France

EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.

$28.2M raised

Feb 2025

Series B

Top Investors

BpifranceAndera PartnersSCI VenturesDavid LamondStephane Boissel

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has EG 427 raised?

EG 427 has raised $28.2M in total funding. The most recent round was Series B. The last funding was announced in February 2025.

Who are EG 427's investors?

EG 427's investors include Bpifrance, Andera Partners, SCI Ventures, David Lamond, Stephane Boissel.

Where is EG 427 headquartered?

EG 427 is headquartered in Paris, France.

What does EG 427 do?

EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.

What stage is EG 427 at?

EG 427 is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 20, 2025.

MLA

"EG 427 — Funding & Investors." VCBacked, February 20, 2025, https://www.vcbacked.co/company/eg-427. Accessed June 3, 2026.

APA

VCBacked. (2025). EG 427 — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/eg-427

Wikipedia (cite web)

{{cite web |title=EG 427 — Funding & Investors |url=https://www.vcbacked.co/company/eg-427 |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 20, 2025.